THERAPIX BIOSCIENCES LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
+27.78% | +53.33% |
| 16/07 | SciSparc Receives Nasdaq Noncompliance Notice | MT |
| 16/07 | SciSparc Seeks Patent for Obesity Drug Ingredient's Composition | MT |
| Sales 2022 | 1.35 112.47 | Sales 2023 | 2.88 240.38 | Capitalization | 25.56L 21Cr |
|---|---|---|---|---|---|
| Net income 2022 | -20L -17Cr | Net income 2023 | -50L -42Cr | EV / Sales 2022 | 11,45,812 x |
| Net cash position 2022 | 35.47L 30Cr | Net cash position 2023 | 50L 42Cr | EV / Sales 2023 | -8,48,893 x |
| P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-0.34
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.98% |
More Fundamentals
* Assessed data
More news
More press releases
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +25.40% | 4.53TCr | |
| +38.38% | 2.43TCr | |
| +26.87% | 1.65TCr | |
| +21.19% | 1.46TCr | |
| +71.91% | 1.43TCr | |
| -0.05% | 678.76Cr | |
| -11.63% | 656.86Cr | |
| +15.08% | 576.04Cr | |
| -8.87% | 572.55Cr |
- Stock Market
- Equities
- SPRC Stock
- TRPXY Stock
